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Abstract
Background—The aim of this study was to provide a contemporary picture of the presentation,
etiology and outcome of infective endocarditis (IE) in a large patient cohort from multiple
locations worldwide.
Methods—Prospective cohort study of 2781 adults with definite IE admitted to 58 hospitals in
25 countries between June 2000 and September 2005.
Results—The median age of the cohort was 57.9 (IQR 43.2–71.8) years and 72% had native
valve IE. Most (77%) patients presented early in the disease (<30 days) with few of the classic
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clinical hallmarks of IE. Recent health-care exposure was found in one quarter of patients.
Staphylococcus aureus was the most common pathogen (31%). Mitral (41%) and aortic (38%)
valves were infected most commonly. Complications were common: stroke (17%); embolization
other than stroke (23%); heart failure (32%) and intracardiac abscess (14%). Surgical therapy was
common (48%) and in-hospital mortality remained high (18%). Prosthetic valve involvement (OR
1.47, 95%CI 1.13–1.90), increasing age (OR 1.30, 95%CI 1.17–1.46 per 10-year interval),
pulmonary edema (OR 1.79, 95%CI 1.39–2.30), S. aureus infection (OR 1.54, 95%CI 1.14–2.08),
coagulase-negative staphylococcal infection (OR 1.50, 95%CI 1.07–2.10), mitral valve vegetation
(OR 1.34, 95%CI 1.06–1.68), and paravalvular complications (OR 2.25, 95%CI 1.64–3.09) were
associated with increased risk of in-hospital death, while viridans streptococcal infection (OR
0.52, 95%CI 0.33–0.81) and surgery (OR 0.61, 95%CI 0.44–0.83) were associated with decreased
risk.
Conclusions—In the early 21st century, IE is more often an acute disease, characterized by a
high rate of S. aureus infection. Mortality remains relatively high.
Infective endocarditis (IE) is a disease of high morbidity and mortality. Although first
described in the mid-sixteenth century, it was Osler's Gulstonian Lectures1–3 to the Royal
College of Physicians in 1885 that created the impetus for systematic study of IE. Beginning
in the early 1900s, investigators have frequently reported on the manifestations of this
disease.4–11 Yet, despite advances over the last century in diagnosis,12 medical therapy,13
and surgical treatment,14, 15 mortality rates have not changed substantially in the past 25
years.5, 9, 16–18 The current in-hospital mortality rate for patients with IE is 15–20%,5, 16
with one-year mortality approaching 40%.16, 18, 19 This is in stark contrast to sustained and
ongoing improvements observed in other cardiovascular diseases such as myocardial
infarction.20
Unfortunately, definitive studies of IE have been limited by its relative infrequency - a
problem compounded by the wide range of causative organisms, at-risk populations, and
underlying risk factors for infection. Most studies have consisted of case reports or single-
center studies which limit the scope and statistical power necessary for definitive
conclusions. Moreover, the lack of multinational studies has prevented an understanding of
how geographic differences in patient characteristics and management affect outcome in
patients with IE.
A prospective multicenter approach is essential for addressing the limitations associated
with prior investigations of IE and, importantly, for examining therapeutic choices in a
definitive way. Therefore, the International Collaboration on Endocarditis (ICE) was
established to facilitate a multinational, multicenter approach to the study of IE. From this
collaboration, the ICE–Prospective Cohort Study (ICE–PCS) was designed to assess the
current characteristics of patients with IE. In this study, we describe this large cohort of
patients, with particular emphasis on the current clinical presentation, microbial etiology and
outcome of patients with IE.
METHODS
International Collaboration on Endocarditis–Prospective Cohort Study
The International Collaboration on Endocarditis (ICE) began in June 1999. The ICE
investigators later developed the ICE–PCS.21 Enrollment in ICE–PCS began on June 2000,
and for the purposes of this study was closed on September 2005; the present study includes
data from 58 sites in 25 countries.
All patients aged 18 years or older with IE from sites that met criteria for participation were
included in the study. Sites had to meet the following criteria: 1) minimum enrollment of 12
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cases per year in a center with access to cardiac surgery; 2) patient identification procedures
in place to ensure consecutive enrollment and minimize ascertainment bias;21 3) high-
quality data, including query resolution; and 4) Institutional Review Board (IRB)/Ethics
Committee approval or waiver based upon local standards.
The ICE-PCS database is maintained at the Duke Clinical Research Institute, which serves
as the coordinating center for the ICE studies, with IRB approval from Duke University
School of Medicine.
Patient Selection
Patients were prospectively identified at each site to ensure consecutive enrollment.21 A
total of 3284 patients were enrolled into ICE-PCS, of which 2781 had definite IE by the
modified Duke criteria (Table 1).22 The 2781 patients with definite IE were included in this
analysis.
Data Collection
A case report form of 275 variables was developed by the ICE group according to standard
definitions.21, 23, 24 Data were collected prospectively by site investigators during the index
hospitalization and were then sent either to the coordinating center for data entry or were
entered directly by the site investigators through a secure internet data entry system. Queries
were developed on critical variables and were distributed to the sites for reconciliation. Once
complete, the reconciled queries were returned to the coordinating center for final data entry.
Definitions
Definitions of the variables included in the ICE-PCS case report form have been reported in
detail elsewhere.23 Community-acquired IE was defined as IE diagnosed at the time of
admission (or within 48 hours of admission) in a patient not fulfilling the criteria for health
care-associated infection. Health care-associated IE was defined as either nosocomial IE or
non-nosocomial health care-associated IE. Nosocomial IE was defined as IE developing in a
patient hospitalized for more than 48 hours prior to onset of signs/symptoms consistent with
IE. Non-nosocomial health care-associated IE was defined as IE diagnosed within 48 hours
of admission in an outpatient with extensive health care contact as reflected by any of the
following criteria: (1) receipt of intravenous therapy, wound care, or specialized nursing
care at home within the 30 days prior to the onset of IE; (2) attendance at a hospital or
hemodialysis clinic or receipt of intravenous chemotherapy within the 30 days prior to the
onset of IE; (3) hospitalization in an acute care hospital for 2 or more days in the 90 days
prior to the onset of IE; or (4) residence in a nursing home or long-term care facility. In an
effort to group centers based on geographic similarities, regions were defined as follows:
North America (10 sites from USA), South America (8 sites from Brazil, Argentina, and
Chile), Europe (22 sites from Croatia, France, Germany, Italy, Netherlands, Spain, Sweden,
Ireland, Romania, Russia, Slovenia and United Kingdom) and Other (18 sites from
Australia, Israel, India, Lebanon, Malaysia, New Zealand, Singapore, Thailand and South
Africa).
Statistical analyses
Continuous variables were represented as medians with 25th and 75th percentiles.
Categorical variables were represented as frequencies and percentages of the specified
group. Univariable comparisons were made with the chi-square test or Kruskal Wallis test as
appropriate. In order to account for the possibility that patients referred to study hospitals
from other health care facilities may represent a different population than those who were
admitted directly, data from the latter group only were analyzed separately where indicated.
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A generalized estimating equation (GEE) method was used to determine factors associated
with in-hospital mortality. Age, gender, whether transferred from another healthcare facility
and variables found to have a univariable association with in-hospital mortality (P <0.10)
were entered into the final exploratory model. The GEE method produces consistent
parameter estimates that measure association between in-hospital death and the baseline
covariates while accounting for the correlation in outcomes of patients from the same
hospital. Likelihood ratio tests were used to compare models with and without interaction
terms. Final parameter estimates were converted to odds ratios (ORs) with corresponding
95% Wald confidence intervals (CIs). The model was validated by the bootstrap procedure.
Some 200 estimates were obtained by fitting the GEE model to 200 datasets obtained by
randomly selecting 2781 observations with replacement from the actual data. Bootstrap
estimates were computed by averaging the 200 parameter estimates and bootstrap
confidence intervals were computed sorting the parameter estimates in ascending order and
selecting the 5th estimate for the lower confidence limit and the 195th estimate for the upper
confidence limit.
Statistical analyses were performed using STATA version 8.2 (StataCorp, College Station,
TX, USA).
RESULTS
Patients were enrolled in ICE–PCS from the following regions: North America (n = 597,
21%); South America (n = 254, 9%); Europe (n = 1213, 44%); and Other (n = 717, 26%).
Baseline characteristics and predisposing factors are shown in Table 2. The median age of
the cohort was 57.9 years (mean 56.5 years; IQR 43.2–71.8 years). The majority of patients
in the cohort (72%) had native valve IE, and most patients (77%) were admitted within one
month of the initial signs of illness. The most common underlying condition was diabetes
mellitus (16%), but 10% of South American patients were diabetics, compared to over one
quarter of North American patients. Similarly, less than 5% of patients from outside North
America were on hemodialysis, compared with over 20% of North American patients.
Predisposing conditions were common in patients with definite IE (Table 2). Although
intravenous drug use remains important (10%), the most common predisposing conditions
were related to valvular heart disease. Degenerative valve disease, e.g. significant mitral
(43%) and/or aortic (26%) valve regurgitation, was the most frequent native valve
predisposing factor. In contrast, rheumatic heart disease was uncommon; only 92 patients
(3%) had rheumatic mitral valve disease. Valvular predisposing conditions also included the
presence of a prosthetic valve in 618 (23%) patients.
Chronic intravenous access was as common as intravenous drug use in the overall cohort;
61% of patients in this study with chronic intravenous access were from North America
(Table 2).
Clinical and laboratory findings on admission are presented in Table 3. The classical signs
that are often considered diagnostic for IE were infrequent.
In 2756 (99%) of the 2781 patients, blood cultures were taken to determine the causative
microorganism. Of the 310 patients (11%) with negative blood cultures, 192 (62%) had
received antibiotics within seven days of the blood culture. In addition to blood culture
information, serologic tests and valve cultures were performed in a minority of cases. Of the
2781 patients, 277 (10%) were determined to have culture/serology-negative IE.
The causative microorganisms isolated from blood cultures are shown in Table 4. Gram-
positive organisms were predominant (83%), with S. aureus accounting for 31% of all
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infections. S. aureus was also the most common organism in each major risk group,
including intravenous drug users and intracardiac device IE (Table 5). Positive serological
tests for Coxiella burnetii were reported from 27 patients (17 from Europe, two from North
America, one from South America and seven from other regions), but only nine were
reported to have reciprocal antibody titers >800. Similarly, 22 patients had positive
serological tests for Bartonella spp. (18 from Europe, one from South America and three
from other regions), but only three were reported to have reciprocal antibody titers >800.
There was one case of infection due to Tropheryma whipplei.
S. aureus was the most common organism in three of four regions, whereas viridans group
streptococci were the most common organisms isolated from patients in South America. The
frequency of Streptococcus bovis IE was much higher in Europe and South America
compared to the other regions, and IE due to HACEK bacteria was relatively uncommon in
North America. The majority of C. burnetii and Bartonella infections were from Europe.
The location of acquisition was determined in 94% of patients; community acquisition
(71%) was more common than nosocomial (14%) or non-nosocomial health care–associated
IE (9%) in the total cohort (Figure 1). North America had a much higher proportion of
health care-associated infections (37%) compared with other regions, mainly due to a larger
proportion with non-nosocomial health care–associated IE. The microbial etiology of IE
varied with location of acquisition, with a higher proportion with staphylococcal IE and a
lower proportion with viridans streptococcal IE among those with health care-associated IE.
Among patients with community-acquired infection, 34% had staphylococcal IE and 23%
had virdans streptococcal IE, while the corresponding figures for nosocomial infection were
70% and 1% respectively, and for non-nosocomial health care-associated infection were
68% and 4% respectively.
Echocardiography was used commonly (99% of patients). More than one half (59%) of the
patients had both transthoracic and transesophageal echocardiography. Of the 2781 patients,
87% had echocardiographic evidence of vegetation, whereas new, significant, valvular
regurgitation was discovered in 64% of patients. Abscess was the most common
paravalvular complication (15% of patients), while 92% of patients with prosthetic valve IE
had evidence of a prosthetic valve complication such as dehiscence or new paravalvular
regurgitation.
Congestive heart failure was the most common complication in all regions (Table 6). In
general, the highest complication rates occurred in North America and Europe.
There were also geographic differences in both treatment and outcome, although the
magnitude of this variation was not large (Table 6). Surgical treatment was common for the
entire cohort, (48%), and in-hospital mortality was 18%. Table 7 shows the results of the
regression modeling for in-hospital mortality, together with the estimates from bootstrap
validation. The following variables were independently associated with an increased risk of
in-hospital death: involvement of a prosthetic valve, increasing age, radiographic pulmonary
edema, S. aureus infection, coagulase-negative staphylococcus infection, presence of a
mitral valve vegetation, and paravalvular complications. Variables independently associated
with a decreased risk of in-hospital death were: elevated ESR, infection with a viridans
group streptococcus, and surgery during the current IE episode. The estimates obtained by
bootstrap validation were similar to those of the original model and support the validity of
this model. Differences between models were noted for four variables: diabetes, health care-
associated acquisition, coagulase-negative staphylococcus infection, and presence of a mitral
valve vegetation.
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Of the total cohort of patients with definite IE, 1174 (42%) had been transferred to a study
hospital from another health care facility. Analysis of the data after excluding these patients
revealed few differences from analysis of the whole cohort (Tables 2, 4, and 6). Notable
differences were that transferred patients were more likely to undergo surgery (63% of
transferred patients cf 37% of non-transferred patients; p <0.001), and were more likely to
have congestive heart failure as a complication (39% cf 27%; p <0.001). In-hospital
mortality (18%) and microbial etiology were similar for both groups of patients.
COMMENT
Despite more than a century of study and recent advances in diagnosis and treatment, IE
remains an incompletely understood disease with high morbidity and mortality. Textbook
descriptions of the clinical features and epidemiology of IE are still largely based on data
obtained from several decades ago. Lack of progress is partly related to the fundamental
difficulty in studying this type of disease. By necessity, most studies are derived from case
reports or small case series from single sites, with few large cohort studies or randomized
trials. A shift in approach is necessary to further the understanding of endocarditis and to
definitively study therapeutic choices. The ICE-PCS represents a new effort in broadening
our understanding of endocarditis. This study is by far the largest prospective cohort study
of IE to date. The size of the cohort coupled with the multinational perspective has enabled
several important observations to be made.
changes in patient characteristics of IE
Our findings reveal that, in much of the world, IE is no longer a subacute or chronic disease
occurring primarily in younger patients with rheumatic valvular abnormalities. In contrast,
most patients in this investigation presented early and demonstrated few of the classic
clinical findings traditionally associated with IE. For example, in the 1960s and 1970s,
Osler's nodes were recorded in 11–23% and splenomegaly in 20–44% of patients with
IE.9, 10, 25, 26 In our study, predisposing valvular conditions were common, but were
primarily due to the presence of degenerative valve disease or a prosthetic valve, rather than
rheumatic heart disease. Forty years ago, approximately 50% of cases of IE in the United
States were superimposed on preexisting rheumatic lesions,27 compared with <5% in the
present study. Prosthetic valve endocarditis was present in one fifth of our patients, as
discussed in detail elsewhere.24
An emerging population at risk for IE consists of patients with healthcare–associated
infections. Overall, IE was attributed to a health care exposure in nearly 25% of the patients.
These findings confirm those of recent reports from small single-center studies16,28 and
provide evidence that these population changes are occurring in many regions of the world.
The health care setting will continue to gain importance in relation to complications such as
IE, mainly due to aging societies that rely upon increasingly invasive medical care.29, 30
Our analysis has provided evidence of geographic differences for several important
characteristics in patients with IE. For example, although the overall IE population
characteristics were influenced by contact with health care services and medical
interventions, this specific finding was not observed in the centers from South America. In
addition, the association between health care-associated IE was most striking in North
America.
changes in microbiologic characteristics of IE
Another observation arising from this investigation is the shift in the microbiology of IE. S.
aureus is now the most common cause of IE in much of the world, confirming several recent
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investigations5, 16, 31 and the earlier findings of the ICE-PCS.23 This shift is due in part to
the global presence of risk factors for S. aureus–associated IE (for example, injection drug
use, health care contact, and invasive procedures). Given the growing antimicrobial
resistance in S. aureus,32 including vancomycin,33–35 the importance of this pathogen as a
potentially lethal infection is cause for concern.
We also noted a substantially higher prevalence of S. bovis IE in Europe, that HACEK IE
was relatively uncommon in North America, and that most cases of Q fever and bartonella
IE came from Europe. Whether these findings reflect differences in patient characteristics,
regional health care access, diagnostic bias or other factors remains to be determined. For IE
due to micro-organisms that are difficult to culture, geographic differences may, at least
partially, reflect variation in the threshold for performing additional diagnostic tests. This
may be the case for Q fever and bartonella IE which often rely on serological and/or nucleic
acid amplification tests for diagnosis.36 However, it is also clear that there are geographic
differences in the incidence of these two infections.37
These changes in the patients and pathogens have important implications for the diagnosis
and management of IE. For example, new risk groups have been identified that necessitate
careful diagnostic attention in the presence of fever and bacteremia. In addition, the acute
nature of IE in the modern era may require an accelerated evaluation strategy that provides
the opportunity for early diagnosis and treatment decisions in patients at high risk for
complications and death.
In-Hospital Mortality
We have found several factors that were independently associated with in-hospital mortality.
Some of these factors, such as increasing age, presence of pulmonary edema, and
paravalvular complications, were not surprising. In addition, prosthetic valve IE and
staphylococcal IE were also associated with an increased risk of in-hospital death, while
there was a decreased risk associated with viridans streptococcal IE. Interestingly, an
elevated ESR was associated with a decreased risk of death, although the reason for this is
unclear. Elevated ESR may be associated with more chronic infection, thereby signifying a
more chronic clinical course. Importantly, we have found that early surgery may be critical
in improving survival in patients with definite IE. This finding adds detail to recent reports
supporting early surgical intervention38, 39 and adds credence to the practice of a combined
medical and surgical approach from admission for patients with IE, specifically in those
with congestive heart failure and prosthetic valve infections. Our finding that nearly 50% of
patients had surgery indicates that the threshold for early surgical treatment has lowered.
Study Limitations
This is an observational study of patients from centers with a particular interest in IE. These
hospitals are typically referral centers with cardiac surgical programs. Consequently, the
study population is unlikely to be a true population-based sample, thereby limiting
epidemiologic inferences. This potential selection bias may be less evident in some sites
(e.g. New Zealand) where most cases of IE within the catchment area would be eligible for
enrollment in the study. It might be expected that patients transferred from other health care
facilities would represent a different population than those who presented directly to study
hospitals. In particular, the former group may have more complicated disease and greater
indications for surgery. However, when the two groups were compared, patients transferred
from other facilities had similar characteristics to those presenting directly to study
hospitals, with notable exceptions being that a larger proportion of the former group
underwent surgery during their initial hospitalization and had congestive heart failure as a
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complication. Consequently, we believe it is important to present data from both groups of
patients and that exclusion of referred patients may create a greater selection bias.
While study sites spanned all non-Antarctic continents, there was a heavy weighting towards
wealthy countries in Europe, North America and Australasia, with few sites in Asia and
Africa. There would undoubtedly be greater geographic differences in patient and
microbiologic characteristics of IE if sampling was able to more closely resemble the global
population distribution. The study lacked long-term follow-up of patients, thereby limiting
the ability to analyze outcome beyond initial hospitalization. The precise timing of all
complications was not recorded and may affect the ability to determine the clinical
significance of some findings.
Conclusions
IE remains a serious and deadly disease despite recent advances in diagnosis and treatment.
Notably, IE has shifted to a disease in which the presentation is more acute than previously
described and, throughout much of the world, is characterized by a high rate of S. aureus
infection in patients with previous health care exposure. More care must be taken to
effectively treat all patients with S. aureus bacteremia and to identify patients with high
potential for complications.40 We have documented geographic differences in the
presentation, microbial etiology, treatment, and outcome of patients with IE. In addition, we
have found initial evidence that early surgery may be important in improving patient
outcomes. Since nearly 50% of patients with IE undergo surgery, early identification of
surgical indications may improve mortality. More research also needs to focus on stroke
prevention (e.g. when to operate on vegetations), the identification of most effective therapy
(e.g. role of new antibiotics and combination treatment), and understanding reasons for the
high prevalence of S. bovis IE in Europe and the near absence of HACEK IE in North
America.
Acknowledgments
In addition to all of the named ICE investigators at each site, we would like to acknowledge the support given to
this project from all of the personnel at each site and at the coordinating center that have allowed this project to
move forward. This study was supported in part by the following: National Institutes of Health grants AI-068804
(VGF) and K23 HL70861-01 (CHC), AHA BGIA 0265405U (CHC), the “Ministerio de Sanidad y Consumo,
Instituto de Salud Carlos III, Madrid (Spain) - Red Española de Investigación en Patología Infecciosa” ((REIPI
RD06/0008) and FIS 05/0170) (JMM), the Fundación Privada Máximo Soriano Jiménez (Barcelona, Spain) (JMM),
the Institut d'Investigacions Biomèdiques August Pi i Sunyer and the “Conselleria de Salut de la Generalitat de
Catalunya, Barcelona (Spain) (IDIBAPS, Barcelona Spain) (JMM).
Role of the Sponsors The sponsors played no role in the design and conduct of the study; collection, management,
analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
Appendix
Study Investigators David Gordon MBBS, PhD, FRACP, FRCPA, Uma Devi MD
(Flinders Medical Centre, Adelaide, Australia); Denis Spelman MD (Alfred Hospital,
Amiens, France); Jan T.M. van der Meer MD, PhD (University of Amsterdam, Amsterdam,
Netherlands); Carol Kauffman MD, Suzanne Bradley MD, William Armstrong MD (Ann
Arbor VA Medical Center, Ann Arbor, USA); Efthymia Giannitsioti MD, Helen
Giamarellou MD, PhD (Attikon University General Hospital, Athens, Greece); Stamatios
Lerakis MD, FAHA, FACC, FASE, FCCP (Emory University, Atlanta, USA); Ana del Rio
MD PhD, Asuncion Moreno MD PhD, Carlos A. Mestres MD, PhD, FETCS, Salvador
Ninot, MD, Carlos Paré MD PhD, Cristina Garcia de la Maria PhD, Yolanda Armero, Elisa
de Lazzari BSc, Francesc Marco MD PhD, Jose M Gatell MD PhD, Manel Almela MD,
Murdoch et al. Page 8
Arch Intern Med. Author manuscript; available in PMC 2013 April 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Manuel Azqueta MD, Marta Sitges, MD PhD, Xavier Claramonte MD, Maria Jesús
Jiménez-Expósito MD PhD, Natividad de Benito MD PhD, Jose Ramirez MS, PhD, Noel
Perez MD, José M. Miró MD, PhD (Hosp. Clinic - IDIBAPS: University of Barcelona,
Barcelona, Spain); Benito Almirante MD, Nuria Fernandez-Hidalgo MD, Pablo Rodriguez
de Vera MD, Pilar Tornos MD, Vicente Falcó MD Xavier Claramonte MD, (Hospital
Universitari Vall d'Hebron, Barcelona, Spain); Nisreen Sidani RN, MSN, Souha Kanj-
Sharara MD, FACP, Zeina Kanafani MD, MS (American University of Beirut Medical
Center, Beirut, Lebanon); Annibale Raglio MD, DTM&H, Antonio Goglio MD, Fabrizio
Gnecchi MD, Fredy Suter MD, Grazia Valsecchi MD, Marco Rizzi MD, Veronica Ravasio
MD (Ospedali Riuniti di Bergamo, Bergamo, Italy); Bruno Hoen MD, PhD, Catherine
Chirouze MD, Efthymia Giannitsioti MD, Joel Leroy MD, Patrick Plesiat MD, Yvette
Bernard MD (University Medical Center of Besançon, Besançon, France); Anna Casey,
Peter Lambert BSc, PhD, DSc, Richard Watkin MRCP, Tom Elliott BM, BS, BMedSci,
PhD, DSc, FRCPath (Queen Elizabeth Hospital, Birmingham, UK); Mukesh Patel MD,
William Dismukes MD (University of Alabama at Birmingham, Birmingham, USA);
Angelo Pan MD, Giampiero Caros MD (Spedali Civili - Università di Brescia, Brescia,
Italy); Amel Brahim Mathiron Christophe Tribouilloy MD, PhD, Thomas Goissen MD
(South Hospital Amiens, Bron Cedex, France); Armelle Delahaye, Francois Delahaye MD,
MPH, FESC, Francois Vandenesch MD, PhD (Hopital Louis Pradel, Bron Cedex, France);
Carla Vizzotti MD, Francisco M. Nacinovich MD, Marcelo Marin MD, Marcelo Trivi MD,
Martin Lombardero MD (Instituto Cardiovascular, Buenos Aires, Argentina); Claudia
Cortes MD, José Horacio Casabé MD (Instituto de Cardiología y Cirugía Cardiovascular,
Buenos Aires, Argentina); Javier Altclas MD, Silvia Kogan MD (Sanatorio Mitre, Buenos
Aires, Argentina); Liliana Clara MD, Marisa Sanchez MD (Hospital Italiano, Buenos Aires,
Argentina); Anita Commerford MD, Cass Hansa MD, Eduan Deetlefs MD, Mpiko Ntsekhe
MD, Patrick Commerford MD (Groote Schuur Hospital, Cape Town, South Africa); Dannah
Wray MD, MHS, Lisa L. Steed PhD, Preston Church MD, Robert Cantey MD (Medical
University of South Carolina, Charleston, USA); Arthur Morris MD, FRCPA (Diagnostic
Medlab, Auckland, New Zealand); David Holland MB, ChB, PhD, FRACP, FRCPA
(Auckland City Hospital, Auckland, New Zealand); David Murdoch MD, MSc, FRACP,
FRCPA, Stephen Chambers MD, MSc, FRACP (University of Otago, Christchurch and
Christchurch Hospital, Christchurch, New Zealand); Kerry Read MB, ChB, FRACP (North
Shore Hospital, Auckland, New Zealand); Nigel Raymond MB, ChB, FRACP (Wellington
Hospital, Wellington, New Zealand); Selwyn Lang MB, ChB, FRACP, FRCPA
(Middlemore Hospital, Auckland, New Zealand); Despina Kotsanas BSc (Hons), Tony M.
Korman MD (Southern Health, Clayton, Australia); Gail Peterson MD, Jon Purcell BS, Paul
M. Southern, Jr. MD (UT-Southwestern Medical Center, Dallas, USA); Manisha Shah MD,
Roger Bedimo MD, MS (Dallas VA Medical Center, Dallas, USA); Arjun Reddy, Donald
Levine MD, Gaurav Dhar MD (Wayne State University, Detroit, USA); Alanna Hanlon-
Feeney, Margaret Hannan MD, BCh, BAO, MSc, MRCPath, FRCPI, Sinead Kelly MD
(Mater Hospitals, Dublin, Ireland); Andrew Wang MD, Christopher H. Cabell MD, MHS,
Christopher W. Woods MD, MPH, Daniel J Sexton MD, Danny Benjamin, Jr MD, MPH,
PhD, G Ralph Corey MD, Jay R McDonald MD, Jeff Federspiel, John J Engemann MD, L.
Barth Reller MD, Laura Drew RN, BSN, L.B. Caram MD, Martin Stryjewski MD, MHS,
Susan Morpeth MB, ChB, Tahaniyat Lalani MD, Vance Fowler, Jr MD, MHS, Vivian Chu
MD (Duke University Medical Center, Durham, USA); Bahram Mazaheri PhD, Carl
Neuerburg, Christoph Naber MD (University Essen, Essen, Germany); Eugene Athan MD,
Margaret Henry BSc (Hons), PhD, Owen Harris MD (Barwon Health, Geelong, Australia);
Eric Alestig MD, Lars Olaison MD,PhD, Lotta Wikstrom, Ulrika Snygg-Martin MD
(Sahlgrenska Universitetssjukhuset/Östra, Goteborg, Sweden); Johnson Francis MD,DM, K
Venugopal MD,DM, Lathi Nair MD, DM, Vinod Thomas MD, DM (Medical College
Calicut, Kerla, India); Jaruwan Chaiworramukkun MD, Orathai Pachirat MD, Ploenchan
Chetchotisakd MD, Tewan Suwanich MD (Khon Kaen University, Khon Kaen, Thailand);
Murdoch et al. Page 9
Arch Intern Med. Author manuscript; available in PMC 2013 April 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Adeeba Kamarulzaman MBBS, FRACP, Syahidah Syed Tamin MD (University of Malaya
Medical Center, Kuala Lumpur, Malaysia); Manica Mueller Premru MD, PhD, Mateja
Logar MD, PhD, Tatjana Lejko-Zupanc MD, PhD (Medical Center Ljublijana, Ljublijana,
Slovenia); Christina Orezzi, John Klein MD (St. Thomas' Hospital, London, UK); Emilio
Bouza MD, PhD, Mar Moreno MD, PhD, Marta Rodríguez-Créixems MD, PhD, Mercedes
Marín MD, Miguel Fernández MD, Patricia Muñoz MD, PhD, Rocío Fernández, Victor
Ramallo MD (Hospital General Universitario Gregorio Marañón, Madrid, Spain); Didier
Raoult MD, PhD, Franck Thuny MD, Gilbert Habib MD, FACC, FESC, Jean-Paul Casalta
MD, Pierre-Edouard Fournier MD (Faculté de Médecine de Marseille, Marseille, France);
Natalia Chipigina PhD, Ozerecky Kirill MD, Tatiana Vinogradova MD, PhD, Vadim P.
Kulichenko PhD (Russian Medical State University, Moscow, Russia); O.M. Butkevich PhD
(Learning Medical Centre of Russian Presidential Affairs Government, Moscow, Russia);
Christine Lion MD, Christine Selton-Suty MD, Francois Alla MD, PhD, Hélène Coyard,
Thanh Doco-Lecompte MD (CHU Nancy-Brabois, Nancy, France); Diana Iarussi MD,
Emanuele Durante-Mangoni MD, PhD, Enrico Ragone MD, PhD, Giovanni Dialetto MD,
Marie Françoise Tripodi MD, Riccardo Utili MD, Roberta Casillo MD, PhD (II Università
di Napoli, Naples, Italy); A. Sampath Kumar MD, Gautam Sharma MD (All India Institute
of Medical Sciences, New Delhi, India ); Stuart A. Dickerman MD (New York University
Medical Center, New York, USA );Alan Street, Damon Peter Eisen MBBS, MD, FRACP,
Emma Sue McBryde MBBS, PhD, FRACP, Leeanne Grigg (Royal Melbourne Hospital,
Parkville, Australia); Elias Abrutyn MD (Drexel University College of Medicine,
Philadelphia, USA); Christian Michelet MD, PhD, Pierre Tattevin MD, Pierre Yves Donnio
PhD (Pontchaillou University, Rennes, France); Claudio Querido Fortes MD (Hospital
Universitario Clementino Fraga Filho/UFRJ, Rio de Janeiro, Brazil ); Jameela Edathodu
MRCP, Mashael Al-Hegelan MD (King Faisal Specialist Hospital & Research Center,
Riyadh, Saudi Arabia); Bernat Font MD, Ignasi Anguera MD, PhD, Joan Raimon Guma MD
(Hospitál de Sabadell, Sabedell, Spain); M Cereceda MD, Miguel J. Oyonarte MD, Rodrigo
Montagna Mella Md (Hospital Clinico Universidad de Chile, Santiago, Chile); Patricia
Garcia MD, Sandra Braun Jones MD (Hosp. Clínico Pont. Universidad Católica de Chile,
Santiago, Chile); Auristela Isabel de Oliveira Ramos MD (Instituto Dante Pazzanese de
Cardiologia, São Paulo, Brazil); Marcelo Goulart Paiva MD, Regina Aparecida de Medeiros
Tranchesi MD (Hospital 9 de Julho, São Paulo, Brazil); Lok Ley Woon BSN, Luh-Nah Lum
BSN, Ru-San Tan MBBS, MRCP (National Heart Centre, Singapore, Singapore); David
Rees MD, Pam Kornecny MD, Richard Lawrence MD, Robyn Dever MD (St. George
Hospital, Sydney, Australia); Jeffrey Post MD, Phillip Jones MD, Suzanne Ryan MHSc,
GCDM (The University of New South Wales, Sydney, Australia ); John Harkness MD,
Michael Feneley MD (St. Vincent's, Sydney, Australia); Ethan Rubinstein MD, LLB, Jacob
Strahilewitz MD (Tel Aviv University School of Medicine, Tel Aviv, Israel); Adina Ionac
MD,PhD, Cristian Mornos MD, Stefan Dragulescu MD,PhD (Victor Babes University of
Medicine and Pharmacy, Timisoar, Romania); Davide Forno MD, Enrico Cecchi MD,
Francesco De Rosa MD, Massimo Imazio MD, FESC, Rita Trinchero MD (Maria Vittoria
Hospital, Torino, Italy); Franz Wiesbauer MD, Rainer Gattringer MD (Vienna General
Hospital, Vienna, Austria); Ethan Rubinstein MD,LLB, Greg Deans MD (University of
Manitoba, Winnipeg, Canada); Arjana Tambic Andrasevic MD, PhD, Bruno Barsic MD,
PhD, Igor Klinar MD, Josip Vincelj MD, PhD, FESC, Suzana Bukovski MD, Vladimir
Krajinovic MD (Univ. Hospital for Infectious Diseases, Zagreb, Croatia).
ICE Coordinating Center, Durham, USA Christopher Cabell MD, MHS, Judy Stafford
MS, Khaula Baloch BA, Paul Pappas MS, Thomas Redick MPH, Tina Harding RN, BSN
ICE Steering Committee A W Karchmer MD, Arnie Bayer MD, Bruno Hoen MD,PhD,
Christopher H Cabell, MD, MHS, Daniel J Sexton, MD, David T. Durack MD, D Phil,
FACP, FRCP, FRACP, Elias Abrutyn MD, Ethan Rubinstein MD,LLB, G Ralph Corey MD,
Murdoch et al. Page 10
Arch Intern Med. Author manuscript; available in PMC 2013 April 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
José M. Miró, MD, PhD, Phillipe Moreillon, Susannah Eykyn, Vance Fowler, Jr, MD, MHS,
Lars Olaison MD, PhD
ICE Publications Committee Arnie Bayer MD, Bruno Hoen MD,PhD, Christopher H
Cabell, MD, MHS, David Murdoch MD, MSc, FRACP, FRCPA, Elias Abrutyn MD,
Eugene Athan MD, José M. Miró, MD, PhD, G Ralph Corey MD, Paul Pappas, MS, Vance
Fowler, Jr, MD, MHS, Vivian Chu, MD
References
1. Osler W. Gulstonian lectures on malignant endocarditis. Lecture I. Lancet. 1885; 1(3210):415–418.
2. Osler W. Gulstonian lectures on malignant endocarditis. Lecture II. Lancet. 1885; 1(3211):459–464.
3. Osler W. Gulstonian lectures on malignant endocarditis. Lecture III. Lancet. 1885; 1(3212):505–
508.
4. Cherubin CE, Neu HC. Infective endocarditis at the Presbyterian Hospital in New York City from
1938-1967. Am J Med. 1971; 51(1):83–96. [PubMed: 5570321]
5. Hoen B, Alla F, Selton-Suty C, et al. Changing profile of infective endocarditis. Results of a 1-year
survey in France. JAMA. 2002; 288(1):75–81. [PubMed: 12090865]
6. Horder TJ. Infective endocarditis: with an analysis of 150 cases and with special reference to the
chronic form of the disease. Quart J Med. 1909; 2:289–329.
7. Lamas CC, Eykyn SJ. Suggested modifications to the Duke criteria for the clinical diagnosis of
native valve and prosthetic valve endocarditis: analysis of 118 pathologically proven cases. Clin
Infect Dis. 1997; 25(3):713–719. [PubMed: 9314466]
8. Osler W. Chronic infective endocarditis. Quart J Med. 1909; 2:219–230.
9. Pelletier LL, Petersdorf RG. Infective endocarditis: a review of 125 cases from the University of
Washington Hospitals, 1963-72. Medicine. 1977; 56(4):287–313. [PubMed: 875718]
10. Rabinovich S, Evans J, Smith IM, January LE. A long-term view of bacterial endocarditis. 337
cases 1924 to 1963. Ann Intern Med. 1965; 63(2):185–198. [PubMed: 14318463]
11. Ribera E, Miró JM, Cortés E, et al. Influence of Human Immunodeficiency Virus 1 infection and
degree of immunosuppression in the clinical characteristics and outcome of infective endocarditis
in intravenous drug users. Arch Intern Med. 1998; 158(18):2043–2050. [PubMed: 9778205]
12. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization
of specific echocardiographic findings. Duke Endocarditis Service. Am J Med. 1994; 96(3):200–
209. [PubMed: 8154507]
13. Bayer AS, Bolger AF, Taubert KA, et al. Diagnosis and management of infective endocarditis and
its complications. Circulation. 1998; 98(25):2936–2948. [PubMed: 9860802]
14. Middlemost S, Wisenbaugh T, Meyerowitz C, et al. A case for early surgery in native left-sided
endocarditis complicated by heart failure: results in 203 patients. J Am Coll Cardiol. 1991; 18(3):
663–667. [PubMed: 1869727]
15. Mullany CJ, Chua YL, Schaff HV, et al. Early and late survival after surgical treatment of culture-
positive active endocarditis. Mayo Clin Proc. 1995; 70(6):517–525. [PubMed: 7776709]
16. Cabell CH, Jollis JG, Peterson GE, et al. Changing patient characteristics and the effect on
mortality in endocarditis. Arch Intern Med. 2002; 162(1):90–94. [PubMed: 11784225]
17. Delahaye F, Goulet V, Lacassin F, et al. Characteristics of infective endocarditis in France in 1991.
a 1-year survey. Eur Heart J. 1995; 16(3):394–401. [PubMed: 7789383]
18. Nissen H, Nielsen PF, Frederiksen M, Helleberg C, Nielsen JS. Native valve infective endocarditis
in the general population: a 10-year survey of the clinical picture during the 1980s. Eur Heart J.
1992; 13(7):872–877. [PubMed: 1644074]
19. Benn M, Hagelskjær LH, Tvede M. Infective endocarditis, 1984 through 1993: a clinical and
microbiological survey. J Intern Med. 1997; 242(1):15–22. [PubMed: 9260562]
20. American Heart Association. Heart disease and stroke statistics - 2004 update. American Heart
Association; Dallas, TX: 2003.
Murdoch et al. Page 11
Arch Intern Med. Author manuscript; available in PMC 2013 April 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
21. Cabell CH, Abrutyn E. Progress toward a global understanding of infective endocarditis. Early
lessons from the International Collaboration on Endocarditis investigation. Infect Dis Clin N Am.
2002; 16(2):255–272.
22. Li J, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of
infective endocarditis. Clin Infect Dis. 2000; 30(4):633–638. [PubMed: 10770721]
23. Fowler VG, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis. A consequence of
medical progress. JAMA. 2005; 293(24):3012–3021. [PubMed: 15972563]
24. Wang A, Athan E, Pappas PA, et al. Contemporary clinical profile and outcome of prosthetic valve
endocarditis. JAMA. 2007; 297(12):1354–1361. [PubMed: 17392239]
25. Lerner PI, Weinstein L. Infective endocarditis in the antibiotic era (continued). N Engl J Med.
1966; 274(5):259–266. [PubMed: 5322870]
26. Venezio FR, Westenfelder GO, Cook FV, Emmerman J, Phair JP. Infective endocarditis in a
community hospital. Arch Intern Med. 1982; 142(4):789–792. [PubMed: 7073419]
27. Weinstein L, Rubin RH. Infective endocarditis - 1973. Prog Cardiovasc Dis. 1973; 16(3):239–274.
[PubMed: 4593514]
28. Spies C, Madison JR, Schatz IJ. Infective endocarditis in patients with end-stage renal disease:
clinical presentation and outcome. Arch Intern Med. 2004; 164(1):71–75. [PubMed: 14718325]
29. U.S. Renal Data System (USRDS). USRDS 1999 annual data report. National Institutes of Health;
Bethesda, MD: 1999.
30. Cabell CH, Heidenreich PA, Chu VH, et al. Increasing rates of cardiac device infections among
Medicare beneficiaries: 1990-1999. Am Heart J. 2004; 147(4):582–586. [PubMed: 15077071]
31. Sanabria TJ, Alpert JS, Goldberg R, Pape LA, Cheeseman SH. Increasing frequency of
staphylococcal infective endocarditis. Experience at a university hospital, 1981 through 1988.
Arch Intern Med. 1990; 150(6):1305–1309. [PubMed: 2353863]
32. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-
associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003; 290(22):2976–
2984. [PubMed: 14665659]
33. Centers for Disease Control. Vancomycin-resistant Staphylococcus aureus - New York, 2004.
MMWR. 2004; 2(3):322–323.
34. Tenover FC, Weigel LM, Appelbaum PC, et al. Vancomycin-resistant Staphylococcus aureus
isolate from a patient in Pennsylvania. Antimicrob Agents Chemother. 2004; 48(1):275–280.
[PubMed: 14693550]
35. Whitener CJ, Park SY, Browne FA, et al. Vancomycin-resistant Staphylococcus aureus in the
absence of vancomycin exposure. Clin Infect Dis. 2004; 38(8):1049–1055. [PubMed: 15095205]
36. Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center. Etiologic
diagnosis of 348 cases. Medicine. 2005; 84(3):162–173. [PubMed: 15879906]
37. Werner M, Fournier P-E, Andersson R, Hogevik H, Raoult D. Bartonella and coxiella antibodies in
334 prospectively studied episodes of infective endocarditis in Sweden. Scand J Infect Dis. 2003;
35(10):724–727. [PubMed: 14606611]
38. Bishara J, Leibovici L, Gartman-Israel D, et al. Long-term outcome of infective endocarditis: the
impact of early surgical intervention. Clin Infect Dis. 2001; 33(10):1636–1643. [PubMed:
11595978]
39. Vikram HR, Buenconsejo J, Hasbun R, Quagliarello VJ. Impact of valve surgery on 6-month
mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis.
JAMA. 2003; 290(24):3207–3214. [PubMed: 14693873]
40. Fowler VG, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus
bacteremia. Arch Intern Med. 2003; 163(17):2066–2072. [PubMed: 14504120]
Murdoch et al. Page 12
Arch Intern Med. Author manuscript; available in PMC 2013 April 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
Geographic comparison of location of acquisition in 2781 patients with definite
endocarditis.
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Table 1
Definition of infective endocarditis according to the modified Duke criteria22
Definite infective endocarditis
 Pathologic criteria
• Microorganisms demonstrated by culture or histologic examination of a vegetation, a vegetation that has embolized, or an
intracardiac abscess specimen; or
• Pathologic lesions; vegetation or intracardiac abscess confirmed by histologic examination showing active endocarditis
 Clinical criteria (see below for definitions)
• 2 major criteria; or
• 1 major criterion and 3 minor criteria; or
• 5 minor criteria
Possible infective endocarditis
• 1 major criterion and 1 minor criterion; or
• 3 minor criteria
Rejected
• Firm alternate diagnosis explaining evidence of infective endocarditis; or
• Resolution of infective endocarditis syndrome with antibiotic therapy for ≤4 days; or
• No pathologic evidence of infective endocarditis at surgery or autopsy, with antibiotic therapy for ≤4 days; or
• Does not meet criteria for possible infective endocarditis, as above
Definition of terms used in the modified Duke criteria for the diagnosis of infective endocarditis (IE):
Major criteria
 Blood culture positive for IE
• Typical microorganisms consistent with IE from 2 separate blood cultures:
• Viridans streptococci, Streptococcus bovis, HACEK group, Staphylococcus aureus; or
• Community-acquired enterococci, in the absence of a primary focus; or
• Microorganisms consistent with IE from persistently positive blood cultures, defined as follows:
• At least 2 positive cultures of blood samples drawn >12 h apart; or
• All of 3 or a majority of ≥4 separate cultures of blood (with first and last sample drawn at least 1 h apart)
• Single positive blood culture for Coxiella burnetii or antiphase I IgG antibody titer >1:800
 Evidence of endocardial involvement
 Echocardiogram positive for IE (TEE recommended in patients with prosthetic valves, rated at least “possible IE” by clinical criteria, or
complicated IE [paravalvular abscess]; TTE as first test in other patients), defined as follows:
• Oscillating intracardiac mass on valve or supporting structures, in the path of regurgitant jets, or on implanted material in the
absence of an alternative anatomic explanation; or
• Abscess; or
• New partial dehiscence of prosthetic valve
 New valvular regurgitation (worsening or changing of pre-existing murmur not sufficient)
Minor criteria
• Predisposition, predisposing heart condition or injection drug use
• Fever, temperature >38°C
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• Vascular phenomena, major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival
hemorrhages, and Janeway's lesions
• Immunologic phenomena: glomerulonephritis, Osler's nodes, Roth's spots, and rheumatoid factor
• Microbiological evidence: positive blood culture but does not meet a major criterion as noted abovea or serological evidence of
active infection with organism consistent with IE
• Echocardiographic minor criteria eliminated
Abbreviations: TEE, transesophageal echocardiography; TTE, transthoracic echocardiography.
a
Excludes single positive cultures for coagulase-negative staphylococci and organisms that do not cause endocarditis.
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Table 2
Baseline characteristics and predisposing conditions in 2781 patients with definite endocarditis. Data are
number (%) unless otherwise stated.
Total Cohort Patients
admitted
directly to
study sites
onlya
Region
P value
for the
difference
in regions
North America South America Europe Other
A. Baseline Characteristics
Age, years (median (IQR)) 57.9 (43.2–71.8) 59.8 (44.2–73.1) 52.9 (44.1–66.4) 56.8 (40.3–70.4) 61.4 (45.1–72.7) 58.0 (40.5–72.9) <0.001
Male gender 1889/2777 (68) 1045/1556 (67) 388/596 (65) 179/254 (70) 873/1212 (72) 449/715 (63) <0.001
First sign to admission < 1
month
2088/2711 (77) 1201/1529 (79) 496/582 (85) 166/244 (68) 896/1174 (76) 530/711 (75) <0.001
Hemodialysis 220/2777 (8) 130/1556 (8) 124/596 (21) 20/254 (8) 49/1210 (4) 27/717 (4) <0.001
Diabetes 447/2764 (16) 261/1550 (17) 158/592 (27) 25/253 (10) 169/1207 (14) 95/712 (13) <0.001
HIV positive 58/2748 (2) 41/1540 (3) 16/594 (3) 4/236 (2) 33/1211 (3) 5/707 (1) 0.02
Cancer 230/2772 (8) 160/1553 (10) 52/596 (9) 15/251 (6) 101/1210 (8) 62/715 (9) 0.56
IE type 0.05
  Native valve 1901/2636 (72) 1048/1471 (71) 411/573 (72) 167/246 (68) 860/1166 (74) 463/651 (71)
  Prosthetic valve 563/2636 (21) 321/1471 (22) 116/573 (20) 66/246 (27) 227/1166 (20) 154/651 (24)
  Pacemaker/ICD 172/2636 (7) 102/1471 (7) 46/573 (8) 13/246 (5) 79/1166 (7) 34/651 (5)
B. Predisposing Conditions
Current IV drug use 268/2746 (10) 157/1540 (10) 93/587 (16) 1/249 (0.4) 113/1203 (9) 61/707 (9) <0.001
Previous IE 222/2780 (8) 138/1557 (9) 66/596 (11) 26/254 (10) 84/1213 (7) 46/717 (6) 0.003
Invasive procedure within
60 days
690/2581 (27) 392/1463 (27) 162/508 (32) 64/247 (26) 289/1145 (25) 175/681 (26) 0.03
Chronic IV access 244/2763 (9) 142/1548 (9) 148/595 (25) 12/251 (5) 56/1205 (5) 28/712 (4) <0.001
Endocavitary device
  Pacemaker 262/2752 (10) 146/1540 (9) 55/595 (9) 23/252 (9) 137/1191 (12) 47/714 (7) 0.005
  ICD 27/2720 (1) 15/1521 (1) 16/593 (3) 0/249 (0) 8/1172 (1) 3/706 (0.4) <0.001
Congenital heart disease 311/2656 (12) 167/1481 (11) 62/582 (11) 53/244 (22) 111/1156 (10) 85/674 (13) <0.001
Native valve predisposition 884/2761 (32) 538/1547 (35) 147/596 (25) 93/252 (37) 370/1201 (31) 274/712 (38) <0.001
Abbreviations: HIV, human immunodeficiency virus; IE = infective endocarditis, IV = intravenous, ICD = implantable cardioverter defibrillator
a
Excludes patients transferred to study hospitals from other health care facilities
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Table 3
Clinical and LAboratory findings on admission in 2781 patients with definite endocarditis and historical
comparisons
Findings Number (%)
Fever >38°C 2322/2428 (96)
Splinter hemorrhages 213/2655 (8)
Osler's nodes 77/2648 (3)
Janeway lesions 123/2650 (5)
Roth spots 50/2649 (2)
Vascular embolic event 456/2665 (17)
Conjunctival hemorrhage 122/2655 (5)
Splenomegaly 284/2662 (11)
New murmur 1068/2232 (48)
Worsening of old murmur 359/1787 (20)
Elevated erythrocyte sedimentation rate 1611/2645 (61)
Elevated C-reactive protein 1632/2650 (62)
Elevated rheumatoid factor 138/2549 (5)
Hematuria 666/2587 (26)
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Table 4
Microbiologic etiology by region in 2781 patients with definite endocarditis.
Total Cohort
n = 2781 n
(%)
Patients
admitted
directly to
study sites
onlya n= 1558 n
(%)
Region
P value for the
difference
between
regions
North
America n =
597 n (%)
South
America n =
254 n (%)
Europe n =
1213 n (%)
Other n =
717 n (%)
S. aureus 869 (31) 487 (31) 256 (43) 43 (17) 339 (28) 231 (32) <0.001
Coag Neg staph. 304 (11) 161 (10) 69 (12) 18 (7) 156 (13) 61 (9) 0.005
Viridans group strep 483 (17) 288 (19) 54 (9) 66 (26) 198 (16) 165 (23) <0.001
S. bovis 165 (6) 101 (7) 9 (2) 17 (7) 116 (10) 23 (3) <0.001
Other strep 162 (6) 101 (7) 38 (6) 16 (6) 66 (5) 42 (6) 0.86
Enterococci 283 (10) 158 (10) 78 (13) 21 (8) 111 (9) 73 (10) 0.05
HACEK 44 (2) 26 (2) 2 (0.3) 6 (2) 19 (2) 17 (2) 0.02
Fungi / yeast 45 (2) 25 (2) 20 (3) 3 (1) 13 (1) 9 (1) 0.002
Polymicrobial 28 (1) 23 (2) 8 (1) 1 (0.4) 13 (1) 6 (1) 0.60
Culture negative 277 (10) 122 (8) 41 (7) 51 (20) 123 (10) 62 (9) <0.001
Other 121 (4) 66 (4) 22 (4) 12 (5) 59 (5) 28 (4) 0.61
Abbreviations : strep = streptococci; HACEK = Haemophilus spp., Aggregatibacter (formerly Actinobacillus) actinomycetemcomitans,
Cardiobacterium hominis, Eikenella corrodens, and Kingella species; PVIE = prosthetic valve infective endocarditis.
a
Excludes patients transferred to study hospitals from other health care facilities
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Table 5
Microbiologic etiology by IE type in 2781 patients with definite endocarditis.
Native Valve IE Intracardiac-Device IE
Drug Abusers (n=237) n
(%)
Non-Drug Abusers (n=1644)
n (%)
PVIE (n=563) n (%) Other devices (n=172)a n
(%)
S. aureus 160 (68) 457 (28) 129 (23) 60 (35)
Coag Neg staph. 7 (3) 148 (9) 95 (17) 45 (26)
Viridans group strep 24 (10) 345 (21) 70 (12) 14 (8)
S. bovis 3 (1) 119 (7) 29 (5) 5 (3)
Other strep 5 (2) 118 (7) 26 (5) 7 (4)
Enterococci 11 (5) 179 (11) 70 (12) 10 (6)
HACEK 0 (0) 30 (2) 13 (2) 1 (1)
Fungi / Yeast 3 (1) 16 (1) 23 (4) 2 (1)
Polymicrobial 6 (3) 16 (1) 5 (1) 0 (0)
Culture negative 12 (5) 154 (9) 65 (12) 18 (11)
Other 6 (3) 62 (4) 38 (7) 10 (6)
Surgical therapy 89/234 (38)b 784/1639 (48) 274/561 (49) 104/172 (61)
In-hospital mortality 23/236 (10)b 281/1643 (17) 131/561 (23) 17/172 (10)
Abbreviations : IE = infective endocarditis; strep = streptococci; HACEK = Haemophilus spp., Aggregatibacter (formerly Actinobacillus)
actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella species; PVIE = prosthetic valve infective endocarditis.
a
Including pacemakers and implantable cardioverter defibrillators.
b
For pure right-sided IE only: 23/107 (22%) had surgical therapy and 6/108 (6%) died in hospital.
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Table 6
vegetation findings, complications, treatment, and outcome in 2781 patients with definite endocarditis
Total Cohort
n (%)
Patients
admitted
directly to
study sites
onlya n (%)
Region P value
for the
difference
between
regions
North
America n
(%)
South
America n
(%)
Europe n (%) Other n (%)
A. Vegetation Findings
Vegetation present 2406/2764 (87) 1325/1545 (86) 530/594 (89) 223/254 (88) 1041/1201 (87) 612/715 (86) 0.257
  AV 1031/2741 (38) 524/1535 (34) 198/593 (33) 117/252 (46) 460/1189 (39) 256/707 (36) 0.003
  MV 1125/2740 (41) 640/1534 (42) 253/593 (43) 103/252 (41) 474/1188 (40) 295/707 (42) 0.70
  TV 323/2741 (12) 177/1534 (12) 107/593 (18) 18/252 (7) 129/1189 (11) 69/707 (10) <0.001
  PV 29/2739 (1) 11/1534 (1) 8/593 (1) 5/252 (2) 7/1187 (1) 9/707 (1) 0.15
B. Complications
  Stroke 462/2727 (17) 225/1528 (15) 118/595 (20) 37252 (15) 199/1169 (17) 108/711 (15) 0.11
  Embolization, non-stroke 611/2709 (23) 324/1524 (21) 139/587 (24) 46/251 (18) 295/1163 (25) 131/708 (19) 0.002
  CHF 876/2713 (32) 414/1527 (27) 207/591 (35) 97/249 (39) 383/1162 (33) 189/711 (27) <0.001
  Intracardiac abscess 389/2707 (14) 176/1522 (12) 101/590 (17) 48/250 (19) 156/1157 (13) 84/710 (12) 0.005
  Persistent positive blood
culture
251/2699 (9) 131/1515 (9) 124/586 (21) 7/250 (3) 82/1153 (7) 38/710 (5) <0.001
  New conduction abnormality 217/2695 (8) 100/1511 (7) 70/591 (12) 25/250 (10) 72/1152 (6) 50/702 (7) <0.001
C. Treatment/Outcome
  Surgical therapy 1335/2769 (48) 574/1549 (37) 268/595 (45) 141/252 (56) 613/1210 (51) 313/712 (44) 0.001
  In-hospital mortality 490/2774 (18) 274/1555 (18) 108/596 (18) 43/254 (17) 231/1210 (19) 108/714 (15) 0.17
Abbreviaitons: AV, aortic valve; MV, mitral valve; TV, tricuspid valve; PV, pulmonic valve; CHF, congestive heart failure.
a
Excludes patients transferred to study hospitals from other health care facilities
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Table 7
Results of multivariable regression modelling of associations with In-hospital death in 2781 patients with
definite endocarditis.
Variablea
Original Model Bootstrap Modelc
ORb 95% CI p-value ORb 95% CI
Age in ten year intervals 1.30 1.17–1.46 <0.001 1.23 1.14–1.31
Male gender 0.99 0.74–1.34 0.97 1.02 0.79–1.25
Transferred from another health care facility 0.97 0.74–1.29 0.85 1.17 0.92–1.42
Prosthetic valve endocarditis 1.47 1.13–1.90 0.004 1.34 1.05–1.70
Hemodialysis 1.06 0.73–1.53 0.76 1.01 0.65–1.42
Diabetes 1.28 0.88–1.86 0.20 1.45 1.08–1.85
Intravenous drug use 0.93 0.51–1.70 0.82 0.81 0.47–1.24
Cancer 1.04 0.65–1.67 0.86 1.23 0.80–1.70
Other chronic illness 1.36 0.95–1.95 0.10 1.28 0.99–1.61
Invasive procedure 0.96 0.66–1.39 0.82 0.94 0.73–1.18
Congenital heart disease 1.22 0.74–2.02 0.44 1.18 0.75–1.61
Elevated erythrocyte sedimentation rate 0.57 0.44–0.73 <0.001 0.59 0.47–0.72
Radiographic pulmonary edema 1.79 1.39–2.30 <0.001 2.03 1.56–2.53
Health care-associated acquisition 1.30 0.85–1.98 0.23 1.32 1.02–1.69
S. aureus IE 1.54 1.14–2.08 0.005 1.72 1.31–2.18
Coagulase-negative staphylococci IE 1.50 1.07–2.10 0.02 1.36 0.93–1.87
Viridans group streptococci IE 0.52 0.33–0.81 0.004 0.52 0.35–0.71
Mitral valve vegetation 1.34 1.06–1.68 0.01 1.20 0.93–1.45
Paravalvular complications 2.25 1.64–3.09 <0.001 2.00 1.57–2.49
Surgery during this episode 0.61 0.44–0.83 0.002 0.56 0.44–0.69
aAll dichotomous variables except for age.
bAdjusted for all other variables in the model.
c
Italicised values indicate differences between the original and bootstrap models
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